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Background
A heterologous prime-boost vaccination strategy using
GVAX pancreas vaccine and CRS-207 is showing pro-
mise in patients with metastatic pancreatic adenocarci-
noma (PDA). GVAX is composed of lethally-irradiated,
allogeneic pancreatic cancer cells modified to express
GM-CSF and induces a broad response against multiple
tumor antigens. GVAX is given with low-dose cyclopho-
sphamide (CY) to inhibit regulatory T cells. CRS-207 is
live-attenuated Listeria monocytogenes engineered to
express the tumor-associated antigen mesothelin. CRS-
207 boosts responses against mesothelin and is unique
in its capacity to stimulate both innate and adaptive
immunity by activating T cells and NK cells. In a
recently completed Phase II study, the CY/GVAX plus
CRS-207 combination resulted in statistically-significant
improvement of overall survival (OS) compared to CY/
GVAX alone (Le, GI ASCO 2014).
Methods
This is a Phase IIb study comparing CY/GVAX and CRS-
207 to chemotherapy or to CRS-207 alone in adults with
previously-treated metastatic PDA. Subjects will be
enrolled in two cohorts: 150 subjects into a primary cohort
of patients with at least two prior treatment regimens for
metastatic disease (3rd+ line) and 90 subjects into an
exploratory cohort of patients with only one prior treat-
ment regimen for metastatic disease (2nd line). Subjects
will be randomized in a 1:1:1 ratio to receive either 2
doses of CY/GVAX and 4 doses of CRS-207 (Arm A),
6 doses of CRS-207 (Arm B) or physician’s choice of select
single-agent chemotherapy (Arm C). The primary objec-
tive is to compare OS in the primary cohort between
Arms A and C. Secondary/exploratory objectives include:
comparison of OS in both primary and exploratory
cohorts between all treatment arms, assessment of safety
and clinical responses (tumor assessments and CA19-9
levels) and correlation of Lm- and mesothelin-specific
T cell and other immunological responses with OS, pro-
gression-free survival and best overall response. (Sponsor:
Aduro BioTech, Inc.; NCT02004262).
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